Monday, April 3, 1995
Univax Biologics Inc.
Robertson, Stephens' Hurwitz also reiterated a "buy" following FDA approval of the Rockville, Md., company's WinRho SD
virally inactivated immune globulin (see BioCentury Extra, March 28). As a stand-alone asset, WinRho is worth $9-10 a share, making the rest of UNVX's promising pipeline a virtual giveaway at current prices, he said.